2018 Early Career Cancer Researchers

20 Dec 2017

Can Too Foundation is proud to announce our 2018 early career cancer researchers!

Can Too-ers have laced up their runners, thrown on a cossie, jumped on a bike and sung on stage to give these innovative researchers the opportunity they need to make a real difference to the research, prevention, care and control of cancer.

To read more about how we're investing in cancer research, click here.

2018 Early Career Cancer Researchers

Dr Angelica Merlot, University of Sydney, NSW

The spread of pancreatic cancer

Exploiting the ER Stress Pathways Against Pancreatic Cancer Metastasis

Dr Nicholas Fletcher, University of Queensland, QLD

New therapies for triple negative breast cancer

Aptamer targeted therapies for triple-negative breast cancer

Dr Lauren Aoude, University of Queensland, QLD

Characteristics of melanoma

Genomics and biological correlates of radiomics in melanoma

Dr Prahlad Raninga, QIMR Berghofer Medical Research Institute, QLD

New treatments for triple negative breast cancer

Targeting thioredoxin reductase 1 in novel combination therapies to treat triple negative breast cancer.

Dr Camille Guillerey, QIMR Berghofer Medical Research Institute

Developing preventative mechanisms for multiple myeloma

Blocking the inhibitory receptor TIGIT to restore immunity against multiple myeloma

Dr Su Yin Lim, Macquarie University, NSW

Immunotherapy for melanoma

Differential effects of MAPK inhibition on immune activity determine melanoma response

Dr Fernando de Souza Fonseca Guimaraes, Walter and Eliza Hall Institute of Medical Research, VIC

Immunotherapy for melanoma

Targeting suppressive TGF-beta to enhance innate lymphoid cell response against melanoma

Dr Sumit Sahni, University of Sydney, NSW

Therapies for pancreatic cancer

Molecular Role of the AMPK-Dependent Pathway in the Activity of Thiosemicarbazones Against Pancreatic Cancer

Dr Yuan Cao, University of Melbourne, VIC

Immunotherapy for breast cancer treatment

Targeting matrix metalloproteinase-12 (MMP12) promotes an immune response against breast cancer

Dr George Sharbeen, Lowy Cancer Research Centre University of NSW, NSW

Developing treatments for pancreatic cancer

MutY-Homolog is a Potential Therapeutic Target for Pancreatic Cancer